🌿 Environment 3d ago · Gwendolyn Wu

Lilly, Foghorn part ways; Wave’s FDA-approved plans

BioPharma Dive
BioPharma industry news
View Channel →
Lilly, Foghorn part ways; Wave’s FDA-approved plans
Source ↗ 👁 0 💬 0
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

Comments (0)

Sign in to join the discussion

More Like This

Climate leaders push for more solar energy by 2030
EHN · 8h ago
‘Wait for the clock to run out’: Louisiana offshore wind energy leaders look beyond Trump
EHN · 8h ago
Clarence Thomas is in the hot seat for US Supreme Court’s biggest climate case in years
EHN · 8h ago
Sea levels on the West Coast to rise by a foot as Kelvin waves hit
EHN · 8h ago
Michigan races to extend public water ahead of huge toxic plume
EHN · 8h ago
Cat foods contain toxic chemicals, investigation finds
EHN · 8h ago